RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immix Biopharma Stock

Immix Biopharma EBIT 2024

Immix Biopharma EBIT

-20.48 M USD

Ticker

IMMX

ISIN

US45258H1068

In 2024, Immix Biopharma's EBIT was -20.48 M USD, a 26.85% increase from the -16.14 M USD EBIT recorded in the previous year.

The Immix Biopharma EBIT history

YEAREBIT (undefined USD)
2029e-
2028e87.06
2027e25.3
2026e-10.3
2025e-21.29
2024e-20.48
2023-16.14
2022-8.22
2021-1.35
2020-0.45
2019-0.84

Immix Biopharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Immix Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Immix Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Immix Biopharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Immix Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Immix Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Immix Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Immix Biopharma’s growth potential.

Immix Biopharma Revenue, EBIT and net profit per share

DateImmix Biopharma RevenueImmix Biopharma EBITImmix Biopharma Net Income
2029e186.65 M undefined0 undefined106.12 M undefined
2028e112.07 M undefined87.06 M undefined76.44 M undefined
2027e49.12 M undefined25.3 M undefined23.24 M undefined
2026e12.38 M undefined-10.3 M undefined-10.36 M undefined
2025e3.06 M undefined-21.29 M undefined-15.4 M undefined
2024e1.02 M undefined-20.48 M undefined-17.92 M undefined
20230 undefined-16.14 M undefined-15.43 M undefined
20220 undefined-8.22 M undefined-8.23 M undefined
20210 undefined-1.35 M undefined-24.38 M undefined
20200 undefined-450,000 undefined-1.15 M undefined
20190 undefined-840,000 undefined-970,000 undefined

Immix Biopharma stock margins

The Immix Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immix Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immix Biopharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Immix Biopharma's sales revenue. A higher gross margin percentage indicates that the Immix Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Immix Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Immix Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Immix Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Immix Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Immix Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Immix Biopharma Margin History

Immix Biopharma Gross marginImmix Biopharma Profit marginImmix Biopharma EBIT marginImmix Biopharma Profit margin
2029e0 %0 %56.85 %
2028e0 %77.68 %68.2 %
2027e0 %51.5 %47.31 %
2026e0 %-83.2 %-83.65 %
2025e0 %-695.75 %-503.25 %
2024e0 %-2,007.4 %-1,756.8 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %

Immix Biopharma Aktienanalyse

What does Immix Biopharma do?

Immix Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Immix Biopharma's EBIT

Immix Biopharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Immix Biopharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Immix Biopharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Immix Biopharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Immix Biopharma stock

How much did Immix Biopharma achieve in EBIT for the current year?

In the current year, Immix Biopharma has achieved an EBIT of -20.48 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Immix Biopharma.

How has the EBIT of Immix Biopharma developed in recent years?

The EBIT of Immix Biopharma has increased by 26.853% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Immix Biopharma?

The EBIT of Immix Biopharma is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Immix Biopharma pay?

Over the past 12 months, Immix Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immix Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Immix Biopharma?

The current dividend yield of Immix Biopharma is .

When does Immix Biopharma pay dividends?

Immix Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immix Biopharma?

Immix Biopharma paid dividends every year for the past 0 years.

What is the dividend of Immix Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immix Biopharma located?

Immix Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immix Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immix Biopharma from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Immix Biopharma pay the last dividend?

The last dividend was paid out on 11/18/2024.

What was the dividend of Immix Biopharma in the year 2023?

In the year 2023, Immix Biopharma distributed 0 USD as dividends.

In which currency does Immix Biopharma pay out the dividend?

The dividends of Immix Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immix Biopharma

Our stock analysis for Immix Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immix Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.